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Aims There are significant sex-specific differences in left ventricular ejection fraction (LVEF), with a higher LVEF being
observed in women. We sought to assess the clinical relevance of an increased LVEF in women and men.
...................................................................................................................................................................................................
Methods
and results
A total of 4632 patients from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An
InteRnational Multicenter) registry (44.8% women; mean age 58.7 ± 13.2 years in men and 59.5 ± 13.3 years in
women, P= 0.05), in whom LVEF was measured by cardiac computed tomography, were categorized according to
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LVEF (low <55%, normal 55–65%, and high >65%). The prevalence of high LVEF was similar in both sexes (33.5%
in women and 32.5% in men, P= 0.46). After 6 years of follow-up, no difference in mortality was observed in
patients with high LVEF in the overall cohort (P= 0.41). When data were stratified by sex, women with high LVEF
died more often from any cause as compared to women with normal LVEF (8.6% vs. 7.1%, log rank P= 0.032),
while an opposite trend was observed in men (5.8% vs. 6.8% in normal LVEF, log rank P= 0.89). Accordingly, a first
order interaction term of male sex and high LVEF was significant (hazard ratios 0.63, 95% confidence intervals
0.41–0.98, P= 0.043) in a Cox regression model of all-cause mortality adjusted for age, cardiovascular risk factors,
and severity of coronary artery disease (CAD).
...................................................................................................................................................................................................
Conclusion Increased LVEF is highly prevalent in patients referred for evaluation of CAD and is associated with an increased
risk of death in women, but not in men. Differentiating between normal and hyperdynamic left ventricles might im-
prove risk stratification in women with CAD.
...................................................................................................................................................................................................
Clinical trial
registration
https://clinicaltrials.gov/ct2/show/NCT01443637.
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Introduction
Left ventricular (LV) function and dimensions are important predic-
tors of morbidity and mortality in various cardiovascular diseases.1–3
Recent experimental and clinical studies indicate that there are signifi-
cant sex- and age-specific differences in baseline left ventricular ejec-
tion fraction (LVEF).4–6 Indeed, LV function is significantly higher in
women than in men, and these differences further augment with
age.4–6 The latter is consistent with the observation that the risk of
cardiovascular events starts at higher LVEF indices in women than in
men.7 Similarly, despite their higher mortality rates, LV function is
relatively better preserved in women with coronary artery disease
(CAD), even when adjusting for age and comorbidities.8 To date, it
remains unclear why LVEF differs between genders, however, the
fact that women with heart failure or acute coronary syndrome
show consistently poorer outcomes as compared to men empha-
sizes the need to better define variables that contribute to the
increased cardiovascular risk in women.9,10
Coronary computed tomography angiography (CCTA) has proved
high accuracy and reproducibility in the evaluation of LV morphology
and function, and computed tomography (CT) measures of abnormal
LVEF have been shown to improve risk stratification in patients with
CAD.11 While the association between impaired LVEF and increased
mortality is well established, the impact of an enhanced, high LVEF on
outcomes in patients with CAD is currently unknown. Thus, given (i)
the discrepancies in male and female cardiovascular risk, (ii) the sex-
dependent differences in LVEF, and (iii) the prognostic importance of
LV function, we aimed to evaluate the impact of high LVEF as assessed
by CCTA on long-term outcomes in women and men referred for
evaluation of CAD in a large international multicentre cohort.
Methods
Study population
The rationale, study design, site-specific patient characteristics, and
follow-up durations of the CONFIRM (COronary CT Angiography
EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) long-
term follow-up registry have previously been described.12 Briefly, the
CONFIRM registry prospectively collects clinical, procedural, and follow-
up data on patients undergoing >_64-detector row CCTA and aims to as-
sess the capability of CCTA findings to predict all-cause mortality. Our
study screened 17 181 patients with 6-year follow-up who underwent
CCTA at 17 centres in 9 countries including Austria, Canada, Germany,
Israel, Italy, Portugal, South Korea, Switzerland, and USA. All patients were
enrolled between 2003 and 2011 as part of the CONFIRM long-term fol-
low-up registry. The following inclusion criteria were applied: age 18 years
or older, an evaluation by CCTA scanner with 64-detector rows or
greater, the presence of interpretable CCTA as well as LVEF, volume as-
sessment by gated CCTA, and absence of structural heart disease. Given
the large number of excluded patients and the associated risk of selection
bias, excluded and included patient cohorts were analysed for baseline dif-
ferences. The study complies with the Declaration of Helsinki, and each
study site received institutional review board approval for all registry pro-
cedures. All study participants provided written informed consent.
Data collection and definition of risk factors
Prior to CCTA scanning, information regarding cardiovascular risk factors
was collected at each site by standardized data collection methods.13
Consistent definitions for cardiac symptoms, risk factors, and angiograph-
ic CAD extent and severity were applied as previously described.12
Symptom presentation was classified into asymptomatic and symptomat-
ic, while symptomatic individuals were further classified into typical chest
pain, atypical chest pain, non-anginal pain, or dyspnoea.
Image acquisition and analysis
CCTA was uniformly acquired at all sites using standardized protocols
and multi-detector row CT scanners consisting of 64-rows or greater. All
CCTA images were analysed in a uniform fashion at each site by at least
one highly experienced reader who was Level III equivalent with experi-
ence in interpreting several thousand CCTA scans in direct accordance
with the Society of Cardiovascular Computed Tomography (SCCT)
guidelines14 and/or board certified in cardiovascular CT. Scanning param-
eters, dose reduction strategies, and post-processing imaging techniques
used in the CONFIRM registry have been described in detail else-
where.11,13 LVEF was measured volumetrically (excluding papillary
2 C. Gebhard et al.
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muscles) with post-processing by using 10–20 phases of the cardiac cycle
(temporal resolution, 83–350 ms). LVEF was automatically calculated
using end-diastolic (EDV) and end-systolic (ESV) volumes. Indexed values
were obtained by normalizing EDV and ESV to body surface area (BSA).
Coronary segment location was defined according to the recommenda-
tions of the SCCT.15 All segments were assessed for the presence and se-
verity of coronary stenosis. The latter was categorized in non-obstructive
stenosis (=coronary artery segments displaying plaque with a luminal
diameter stenosis 1–49%) and obstructive stenosis (=coronary artery
segments displaying plaque with a luminal diameter stenosis >_50%). CAD
extent was defined by >_50% stenosis in 0, 1, 2, or 3 coronary artery ves-
sels. In the overall cohort, LVEF was classified as follows: low (<55%),
normal (55–65%), and high normal (>65%). The upper and lower cut-off
values were chosen based on previously reported reference ranges.11,16
In addition, sex-specific upper and lower limits of normal were applied
according to data derived from populations free of cardiovascular dis-
ease.6,17 Sex-specific LVEF strata were as follows: men: low LVEF <47%,
normal LVEF 47–70%, high LVEF >70%; women: low LVEF <50%, normal
LVEF 50–72%, high LVEF >72%. A small heart was defined as an abnor-
mally low LVESV according to reference ranges derived from healthy fe-
male populations.17 Cut-off values to define a small heart were LVESV
<25 mL and indexed LVESV <16 mL/m2, respectively.
Endpoints
The primary outcome measure for the present study was time to death
by any causes. Secondary exploratory outcomes were late revasculariza-
tion and major adverse cardiovascular events (MACE). The latter
included a combination of all-cause mortality and non-fatal myocardial in-
farction (MI) and was assessed in a subcohort of 1359 patients. Cause of
death was not obtained in the CONFIRM registry. Non-fatal MI was
defined as evidence of myocardial necrosis consistent with myocardial is-
chaemia, as detected by changes in cardiac biomarkers together with
symptoms of ischaemia, electrocardiogram changes, or imaging evidence.
Statistical analysis
Baseline characteristics of the study population were summarized
according to sex, with categorical variables being presented as counts
with percentages and continuous variables as mean ± standard deviation.
Differences between continuous and categorical variables were analysed
by the Student’s t-test and the v2 test, or the Fisher’s exact test, as appro-
priate. Kaplan–Meier curves with log-rank test were used to assess the
relationship between LVEF and primary and secondary endpoints.
Hazard ratios (HR) with 95% confidence intervals (CI) for the association
of a high LVEF with all-cause mortality were calculated by use of unadjust-
ed and adjusted Cox proportional hazard regression models. For Cox
proportional hazards modelling the assumption of proportional hazards
was assessed and verified using Schoenfeld residuals (P= 0.253). The Cox
regression analysis was adjusted for age, cardiovascular risk factors includ-
ing smoking, diabetes mellitus, hypertension, dyslipidaemia, positive family
history of CAD, and severity of CAD. A first order interaction term con-
sisting of sex and LVEF was tested in these models to assess the impact of
sex on study outcomes. All analyses were performed using STATA ver-
sion 12.0 (StataCorp LP, College Station, TX, USA), and a P-value <0.05
was considered significant.
Results
Patient characteristics
Out of 17 181 patients, LVEF had been analysed in 4654 patients. For
22 individuals, data on age, gender, or severity of CAD were missing.
Thus, the final analytic sample comprised 4632 patients [2555
(55.2%) men, Figure 1]. No significant difference was found between
excluded and included individuals for baseline demographics (dia-
betes: 17.4% vs. 17.6%, P= 0.69; hypertension: 62.8% vs. 61.4%,
P= 0.106; dyslipidaemia: 59.9% vs. 61.3%, P= 0.081), except for age:
59.3 ± 12.6 vs. 59.1± 13.2 years, P= 0.04). Mean age of our study
population was 59.5± 13.3 years for women and 58.7 ± 13.2 years
for men (P= 0.05 for men vs. women) with 62.9% of women and
61.6% of men (P= 0.4 for men vs. women) being older than 55 years.
Body mass index (BMI) was slightly higher in women as compared to
men (28.0± 6.9 vs. 27.9 ± 4.9, P= 0.02), while BSA was higher in men
(1.8± 0.2 vs. 2.0± 0.2, P< 0.001). Women had less often dyslipidae-
mia than men (59.0% vs. 63.2%, P= 0.004) and more often a positive
family history of CAD (45.9% vs. 39.9%, P< 0.001). Women were
more often symptomatic (82.6% vs. 69.5%, P< 0.001) and suffered
more often from atypical chest pain than men (39.3% vs. 30.3%,
P< 0.001). More men than women had known CAD (13.1% vs. 6.3%,
P< 0.001, Table 1). All demographic characteristics of the study
population stratified by sex are listed in Table 1.
CCTA findings
Mean LVEF was higher in women as compared to men (61.5± 11.2%
vs. 60.2± 11.8%, P= 0.01, Table 2). Also, EDV and ESV were smaller
in women as compared to men (113.7 ± 30.4 vs. 142.5 ± 38.3 mL,
P< 0.001 and 37.8± 20.4 vs. 52.4 ± 28.9 mL, P< 0.001, respectively).
In addition, more women than men had smaller hearts, defined as an
abnormally low LVESV according to previously published data in a
healthy cohort17 (P< 0.001, Table 2). More men than women had a
reduced LVEF <55% (24.7% vs. 19.9%, P< 0.001, Table 2), while LVEF
in women was more often within the normal range (>_55% to <_65%)
as compared to men (46.6% vs. 42.9%, P= 0.012, Table 2). No sex dif-
ference was observed in the prevalence of LVEF >65% (32.5% vs.
33.5%, P= 0.5, Table 2), while more women than men had a very high
(>72%) LVEF (16.3% vs. 12.8%, P= 0.001, Table 2). Overall, men had
more often obstructive CAD (45.2% vs. 33.0% in women, P< 0.001)
and non-obstructive CAD (28.1% vs. 21.4% in women, P< 0.001) as
compared to women, while more women than men were found to
be free of CAD (45.6% vs. 26.6%, P< 0.001). Accordingly, two- and
three-vessel disease was more often observed in men as compared
to women (P< 0.001, Table 2). CCTA findings stratified by sex are
listed in Table 2.
Baseline risk and extent of CAD
according to LVEF strata
Table 3 shows demographic characteristics and CCTA findings of the
total study population stratified by LVEF and sex. Women with high
LVEF tend to be slightly older than men with high LVEF (62.2± 12.8
vs. 60.5 ± 12.5 years, P= 0.008, Table 3) and men with high LVEF
were more often dyslipidaemic than women with high LVEF (68.0%
vs. 62.1%, P= 0.016, Table 3), while no sex differences in other car-
diovascular risk factors were found in patients with high LVEF
(Table 3). Women with high LVEF had a lower prevalence of ob-
structive CAD than men (25.9% vs. 36.9%, P< 0.001) and more
women than men with high LVEF had a small heart defined as an ab-
normally low LVESV (P< 0.001, Table 3).
High left ventricular ejection fraction and mortality 3
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Clinical endpoints
After 6 years of follow-up, all-cause mortality was significantly higher
in patients with impaired LVEF as compared to patients with normal
LVEF (15.3% vs. 7.0%, P< 0.001), while no difference in mortality was
observed in patients with high LVEF (7.1% vs. 7.0% in normal LVEF,
P= 0.41). When data were stratified by sex, cumulative mortality
over 6 years of follow-up was significantly higher in women with
LVEF >65% as compared to men (8.6% vs. 5.8%, P= 0.031, Figure 2A).
The increased mortality in women with high normal LVEF was par-
ticularly pronounced in patients with obstructive (>_50%) CAD
(16.3% in women vs. 7.5% in men, P= 0.003, Figure 2B). In contrast,
no sex differences in outcomes of patients with LVEF >65%
were observed with regard to MACE (P= 0.8, Figure 2C) and late
revascularization (P= 0.1, Figure 2D). When survival during 6 years of
Figure 1 Stydy cohort. Flow-chart demonstrating eligible study patients selected on pre-defined criteria. The final study population comprised
4632 patients.
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of the study population stratified by sex
Baseline characteristics (total n5 4632) Total (n5 4632) Women (n5 2077) Men (n5 2555) P-value
Age (years), mean ± SD 59.1 ± 13.2 59.5 ± 13.3 58.7 ± 13.2 0.05
Age >_55 years, n (%) 2880 (62.2) 1306 (62.9) 1574 (61.6) 0.4
BMI (kg/m2), mean ± SD 28.0 ± 5.8 28.0 ± 6.9 27.9 ± 4.9 0.02
BSA (m2), mean ± SD 1.9 ± 0.2 1.8 ± 0.2 2.0 ± 0.2 <0.001
Smoking, n (%) 897 (19.4) 376 (18.1) 521 (20.4) 0.05
Hypertension, n (%) 2840 (61.4) 1306 (63.0) 1534 (60.2) 0.05
Diabetes mellitus, n (%) 815 (17.6) 381 (18.4) 434 (17.0) 0.2
Family history of CAD, n (%) 1966 (42.6) 949 (45.9) 1017 (39.9) <0.001
Dyslipidaemia, n (%) 2835 (61.3) 1224 (59.0) 1611 (63.2) 0.004
Symptoms, n (%) <0.001
Asymptomatic 1002 (24.5) 327 (17.4) 675 (30.5) <0.001
Non-anginal chest pain 845 (20.6) 388 (20.6) 457 (20.7) 0.9
Atypical chest pain 1411 (34.5) 741 (39.3) 670 (30.3) <0.001
Typical chest pain 837 (20.4) 429 (22.8) 408 (18.5) 0.001
Dyspnoea 1463 (35.1) 806 (41.9) 657 (29.3) <0.001
Prior CAD (MI/PTCA/CABG) 465 (10.0) 131 (6.3) 334 (13.1) <0.001
BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass graft; CAD, coronary artery disease; MI, myocardial infarction; PTCA, percutaneous coronary
intervention.
4 C. Gebhard et al.
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follow-up was compared between low, normal, and high LVEF strata,
all-cause mortality rates were significantly higher in women with high
LVEF as compared to women with normal LVEF (log rank P= 0.0317
vs. normal LVEF, Figure 3A), while no differences were observed in
men (log rank P= 0.9 vs. normal LVEF, Figure 3B). In both, men and
women, low LVEF <55% was associated with reduced survival (log
rank P< 0.001 vs. normal LVEF, Figure 3B and C). The difference in all-
cause mortality between women with high and normal LVEF was
most pronounced in patients with obstructive CAD (log rank
P= 0.0297 vs. normal LVEF, Figure 3C and D). Similar tendencies were
found when patients free of obstructive CAD were analysed
(Figure 4A and B), however, the difference in survival rate between
women with high and normal LVEF did not reach statistical signifi-
cance (log rank P= 0.07 vs. normal LVEF, Figure 4A). In contrast, in
patients with non-obstructive CAD (1–49% coronary stenosis), no
significant differences between high LVEF and normal LVEF strata
were seen in both, women (cumulative mortality: log rank P= 0.89
for high vs. normal LVEF) and men (cumulative mortality: log rank
P= 0.97 for high vs. normal LVEF). Furthermore, no differences in the
occurrence of the endpoints MACE (non-fatal MI and all-cause mor-
tality) or MACE/late revascularization or non-fatal MI (as single event)
were observed in individuals with high LVEF (MACE: Figure 4C and D,
MACE/late revascularization: log rank P= 0.48 for high normal vs.
normal LVEF in women and P= 0.61 for high normal vs. normal LVEF
in men, non-fatal MI: log rank P= 0.15 for high normal vs. normal
LVEF in women and P= 0.39 for high normal vs. normal LVEF in
men). When the overall higher LVEF in women was taken into ac-
count and sex-specific cut-off values for normal/abnormal LVEF were
applied, similar trends and differences in outcomes were observed
(Figures 5A and B and 6A–D). Notably, in this sex-specific analysis,
mortality rates in women with obstructive CAD and high LVEF were
as high as mortality rates in the impaired LVEF group (Figure 5B).
Prognostic value of high LVEF
When the predictive value of LVEF was assessed in a multivariable
Cox regression model adjusted for age, cardiovascular risk factors,
and severity of CAD, high LVEF was not associated with an increased
risk of 6-year mortality as a main effect variable in the overall popula-
tion (n= 4632, Table 4). In contrast, a first order interaction term of
male sex and high LVEF was significant (HR 0.63, 95% CI 0.41–0.98,
P= 0.043), thereby confirming that the association of high LVEF and
mortality is sex dependent. Notably, no significant interaction be-
tween the two covariates age and high LVEF was observed in both,
women and men (age LVEF > 65% in women: HR 0.99, 95% CI
0.96–1.01, P= 0.46 and age LVEF > 65% in men: HR 1.00, 95% CI
0.97–1.03, P= 0.93) and inclusion of the interaction term did not re-
sult in a significant bias in main effect regression. This was also true
when sex-specific LVEF cut-off values for LVEF were included in the
interaction analysis (age LVEF > 72% in women: P= 0.14 and
age LVEF > 70% in men P= 0.661).
Discussion
It is increasingly recognized that women manifest cardiovascular dis-
ease in ways different from men. Our study is the first to report a dif-
ferential prognostic value of high LVEF in women and men. In our
cohort of 4632 patients undergoing CCTA for evaluation of CAD,
we observed that a high LVEF (>65%) was present in 33% of patients
and was associated with an increased risk of all-cause mortality in
women, but not in men. This risk increase was even more
....................................................................................................................................................................................................................
Table 2 Cardiac CT findings of study cohort stratified by sex
Cardiac CT findings Women (n5 2077) Men (n5 2555) P-value
LVEF (%), mean ± SD 61.5 ± 11.2 60.2 ± 11.8 0.01
EDV (mL), mean ± SD 113.7 ± 30.4 142.5 ± 38.3 <0.001
ESV (mL), mean ± SD 37.8 ± 20.4 52.4 ± 28.9 <0.001
EDV/BSA (mL/m2), mean ± SD 64.9 ± 15.3 70.4 ± 18.4 <0.001
ESV/BSA (mL/m2), mean ± SD 21.4 ± 10.7 25.9 ± 14.0 <0.001
Small heart: ESV <25 mL, n (%) 145 (22.9) 72 (7.9) <0.001
Small heart: ESV/BSA <16 mL/m2, n (%) 193 (31.0) 161 (18.1) <0.001
LVEF <55%, n (%) 414 (19.9) 630 (24.7) <0.001
LVEF >_55 to <_65%, n (%) 968 (46.6) 1096 (42.9) 0.01
LVEF >65%, n (%) 695 (33.5) 829 (32.5) 0.5
LVEF >70%, n (%) 429 (20.7) 438 (17.1) 0.002
LVEF >72%, n (%) 338 (16.3) 326 (12.8) 0.001
Extent and severity of CAD, n (%) <0.001
No CAD 946 (45.6) 680 (26.6) <0.001
Non-obstructive (<50%) CAD 445 (21.4) 719 (28.1) <0.001
Obstructive (>50%) CAD 686 (33.0) 1156 (45.2) <0.001
One vessel CAD 340 (16.4) 463 (18.1) 0.1
Two-vessel CAD 168 (8.1) 312 (12.2) <0.001
Three-vessel CAD 178 (8.6) 381 (14.9) <0.001
BSA, body surface area; CAD, coronary artery disease; EDV, end-diastolic volume; ESV, end-systolic volume; LVEF, left ventricular ejection fraction.
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pronounced in women with obstructive CAD and when sex-specific
cut-off values for LVEF were applied. Accordingly, a first order inter-
action term of female sex and high LVEF was identified as a significant
predictor of mortality in a fully adjusted Cox regression model.
In accordance with published literature, we found that 6-year mor-
tality was highest in patients with low LVEF. However, the fact that
women with enhanced baseline LVEF encountered higher mortality
rates than men or women with normal LVEF is a newly documented
finding in patients with stable CAD. Only two previous studies have
assessed the prognostic impact of high LVEF in the acute care setting.
Consistent with our results, Saab et al.16 reported an increase in 60-
day mortality in women with LVEF >65% and acute coronary syn-
drome, while Paonessa et al.18 observed that patients with LVEF
>70% admitted to an intensive care unit experienced an increased
28-day mortality as compared to those with normal LVEF. In their
study, high LVEF was associated with female sex, increased age, and
the diagnoses of hypertension and cancer.18 The mechanisms
accounting for the female propensity towards worse outcomes
amongst patients with enhanced LVEF are not understood.
In our study, we did not observe significant sex differences in the
prevalence of cardiovascular risk factors in patients with high LVEF,
except for a higher rate of dyslipidaemia in men. In addition, women
in the high LVEF strata were more often symptomatic and on average
1.7 years older than men in this group, while both, women and men
with high LVEF were 5 and 3.4 years older than their counterparts in
the normal LVEF population. The latter is consistent with the obser-
vation of a stronger age-dependent increase in LVEF in women as
compared to men.5,6,19 However, the longer life expectancy in
women, as well as the non-significant interaction of age and LVEF in
our Cox regression models for all-cause mortality, suggest that
increasing age is unlikely to be the major explanation of our
findings.20
Although our observational study does not elucidate underlying
mechanisms accounting for these sex differences, recent studies have
Figure 2 Cumulation clinical endpoints during 6 years of follow-up. (A) Six-year mortality (of any cause) rates in total study cohort. (B) Six-year
mortality (of any cause) rates in patients with obstructive (>50%) CAD. (C) Six-year rate of MACE in total cohort. (D) Six-year rate of late revascula-
rization in total cohort. P-values for men vs. women are indicated (bar graph) as well as P-values (ANOVA) for group comparison among different
LVEF strata for each sex (right upper corner).
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..suggested that myocyte hypertrophy due to an increase in aortic stiff-
ness and enhanced afterload in older subjects may account for an
age-dependent increase in LVEF.5,21–23 Furthermore, a progressive
myocyte loss in aged men, but not in women, was observed in a post-
mortem analysis and may account for the sex differences in LV func-
tion.24 Reduced testosterone levels and reduced physical activity in
older men have been suggested to account for these findings.24,25
Interestingly, in our study, the prevalence of small hearts, defined as
an abnormally low LVESV was twice as high in women with high
LVEF as compared to men, which confirms previous reports indicat-
ing that small hearts are more common in women.6,19 This profound
sex difference in heart size in individuals with high LVEF raises the
question whether women with smaller hearts live under constant
hyperdynamic conditions to compensate for the disadvantage of
smaller ventricular volumes. The latter might predispose them to
enhanced cardiac vulnerability in high-stress situations and might, at
least in part, account for the higher mortality observed in this popula-
tion. Indeed, Paonessa et al.18 reported in their study that patients
with LVEF >70% were more likely to suffer from cardiac arrest or
ventricular fibrillation as compared to patients in the normal LVEF
group. Findings consistent with this hypothesis are that women have
higher baseline sympathetic activity and increased sympathetic out-
flow during heart failure or acute coronary syndrome as compared
to men.26–28 Furthermore, an enhanced sympathetic tone, as
assessed by chronotropic responses during vasodilator stress, has
been observed in patients with myocardial ischaemia, which, in turn,
was associated with an increased risk of cardiac death.29–32 Although
myocardial ischaemic burden was not assessed in our CCTA study,
an enhanced sympathetic response in women with high normal LVEF
and ongoing ischaemia might account for the increased mortality
observed in women with high LVEF and obstructive CAD in our
study. Of note, however, myocardial ischaemia might also be present
in individuals without significant epicardial CAD (Ischaemia and No
Obstructive Coronary Artery disease, INOCA), a condition that is
more common in women and referred to as coronary microvascular
dysfunction.33 Interestingly, LV hypercontractility and cardiac sympa-
thetic hyperactivity have been observed in patients with coronary
microvascular dysfunction in one previous study.34 Given the proven
benefits of sympathoinhibition on metabolic and cardiovascular func-
tions in many disease states, the possibility of an augmented sympa-
thetic drive to the heart and vascular bed in women with high LVEF
warrants further investigation.35–37 In addition, future studies will
Figure 3 Survival (Kaplan–Meier curves) during 6 years of follow-up according to LVEF (low <55%, normal 55%–65%, high normal >65%) in men
and women. (A) Survival in women (n= 2077). (B) Survival in men (n= 2555). (C) Survival in women with obstructive CAD (n= 686). (D) Survival in
men with obstructive CAD (n= 1156). Log rank P-values are indicated.
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Figure 4 Event-free survival (Kaplan–Meier curves) during 6 years of follow-up according to LVEF (low <55%, normal 55%–65%, high normal
>65%) in men and women. (A) Survival in women free of obstructive CAD (n= 1391). (B) Survival in men free of obstructive CAD (n= 1399). (C)
Event-free survival from MACE (all-cause mortality and non-fatal MI) in women. (D) Event-free survival MACE in men. Log rank P-values are
indicated.
Figure 5 Sex-specific upper and lower limits of normal LVEF. All-cause mortality during 6 years of follow-up. Women: low LVEF <50%, normal
LVEF >_50% to <_72%, high LVEF >72%. Men: low LVEF <47%, normal LVEF >_47% to <_70%, high LVEF >70%. (A) Six-year mortality (of any cause)
rates in total study cohort. (B) Six-year mortality (of any cause) rates in patients with obstructive (>50%) CAD. P-values for men vs. women are indi-
cated (bar graph) as well as P-values (ANOVA) for group comparison among different LVEF strata for each sex (right upper corner).
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..have to explore whether the combination of INOCA and a high
LVEF might result in a survival detriment in patients affected by this
condition.
Interestingly, increasing evidence suggests that coronary micro-
vascular dysfunction shares common pathophysiological pathways
with the development and progression of heart failure with
preserved ejection fraction,38–42 a disease that is characterized by
impaired LV relaxation, elevated LV filling pressures, and a hypertro-
phied, non-dilated LV.43 Post-menopausal women are more prone to
develop the disease.43 Similarly, diastolic filling abnormalities are a
common finding in elderly women and are associated with increased
mortality.44 Although we found no sex difference in the prevalence
of hypertension in patients with high LVEF, we cannot exclude an in-
fluence of loading conditions, LV mass, or afterload on our study end-
points as these parameters were not quantified in our cohort. In fact,
as elderly women with hypertrophic hearts might be particularly sus-
ceptible to oxygen supply-mediated ischaemia and worse out-
comes,45 a higher prevalence of LV hypertrophy in elderly women
might have accounted for the particularly pronounced survival detri-
ment observed in women with high LVEF and obstructive CAD in
our study. Of note, however, an increasing body of evidence sup-
ports the notion that ESV is commonly increased in these patients,
thus, yielding a lower—and not a high—LVEF.46–49 A recent cardio-
vascular magnetic resonance study even described a significantly
reduced myocardial contraction in LV hypertrophy, independent of
aetiology.50 Interestingly, a primary increase in cardiac output has
only been seen in patients with borderline hypertension, and an
................................................................................................
.................................................................................................
Table 4 Cox regression analysis for all-cause mortal-
ity adjusted by age, cardiovascular risk factors, and se-
verity of coronary artery disease
Risk estimates for all-cause mortality
Total population (n54632)
Predictor HR 95% CI P-value
LVEF >65% 1.02 0.75–1.39 0.89
Male sex 1.05 0.84–1.32 0.645
Interaction term: male sex LVEF >65% 0.63 0.41–0.98 0.043
LVEF, left ventricular ejection fraction.
Figure 6 Sex-specific upper and lower limits of normal LVEF. Survival (Kaplan–Meier curves) during 6 years of follow-up according to LVEF. Men:
low LVEF <50%, normal LVEF >_50% to <_72%, high LVEF >72%. Women: low LVEF <47%, normal LVEF >_47% to <_70%, high LVEF >70%. (A)
Survival in women (n= 2077). (B) Survival in men (n= 2555). (C) Survival in women with obstructive CAD (n= 686). (D) Survival in men with ob-
structive CAD (n= 1156). Log rank P-values are indicated.
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.
augmented sympathetic outflow has been suggested to account for
the elevation of both cardiac output and vascular resistance in these
patients.51,52 Similar to apparent hypertension, borderline hyperten-
sion has been associated with an elevated risk of death.53
There are limitations to this study that should be pointed out.
First, our study is observational. We report the frequency of high
LVEF and its association with adverse long-term outcomes in patients
referred for evaluation for CAD. Our study does not provide infor-
mation on the underling mechanism. Second, our study has the inher-
ent limitations of an open-label registry, including intersite variability
in image acquisition and analysis, inclusion of a relatively heteroge-
neous group of patients, and residual confounding. In fact, we cannot
completely rule out the potential impact of variables not accounted
for in our regression model (e.g. comorbidities such as cancer or in-
fectious disease or the presence of myocardial ischaemia) on our
study endpoints. Third, as currently no definition of a ‘small heart’
exists, cut-off values for abnormally low ESVs were taken from a
healthy female reference population.17 Accordingly, discrepancies
exist regarding comorbidities and morphometric characteristics be-
tween this reference population and our cohort resulting in a higher
prevalence of ‘small hearts’ in our study when indexed cut-off values
for low ESV were applied as compared to non-indexed ESV. Finally,
LVEF is pre- and afterload dependent and is not an intrinsic measure
of contractility. As measures of contractility and afterload (e.g. blood
pressure, pulse wave velocity) were not available in our CT registry,
it remains unknown whether the higher LVEF in women vs. men is
due to differences in contractile state or loading conditions.
However, LVEF is widely used in clinical decision-making, thus, we
believe that the observed sex differences demonstrated in our study
have clinical relevance irrespective of their underlying cause.
In summary, in this large international multicentre cohort, we
observed a significant increase in long-term mortality in women with
high LVEF; this survival detriment was particularly pronounced in a
subgroup of women with obstructive CAD. Our findings indicate
that a high LVEF might exert detrimental effects in women. Our study
emphasizes the need for sex-specific criteria in clinical decision-mak-
ing and suggests that an upper cut-off value for normal LVEF may pro-
vide additional prognostic information in women with CAD. Given
the high prevalence of high LVEF in patients referred for evaluation of
CAD, further research is warranted to decipher the pathophysiologic
process(es) related to the survival detriment in women with
increased LVEF and to determine the role of the sympathetic nervous
system in the development and clinical course of an increased LVEF.
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